{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=15", "query": { "intervention": "bispecific antibody", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 362, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T14:58:59.235Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07111520", "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2025-09-22", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 11, "location_summary": "Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07111520" }, { "nct_id": "NCT05293496", "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Castration-Resistant Prostatic Cancer", "Malignant Melanoma", "Pancreatic Ductal Carcinoma", "Hepatocellular Cancer", "Epithelial Ovarian Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2022-04-19", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Sarasota, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293496" }, { "nct_id": "NCT05032040", "title": "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Clear Cell Carcinoma", "Endometrial Cancer", "Cervical Carcinoma", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "vudalimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2022-07-21", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 17, "location_summary": "Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032040" }, { "nct_id": "NCT06504524", "title": "A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 633, "start_date": "2023-09-01", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06504524" }, { "nct_id": "NCT02370160", "title": "HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory B-Lineage Leukemia", "Relapsed B-Lineage Leukemia", "Refractory B-Lineage Lymphoma", "Relapsed B-Lineage Lymphoma" ], "interventions": [ { "name": "DT2219ARL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 18, "start_date": "2015-12-21", "completion_date": "2018-04-08", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370160" }, { "nct_id": "NCT03192202", "title": "AFM13 in Relapsed/Refractory Cutaneous Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "AFM13", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ahmed Sawas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-07-17", "completion_date": "2020-04-01", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03192202" }, { "nct_id": "NCT03035253", "title": "A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "OMP-305B83", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 16, "start_date": "2016-12", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 6, "location_summary": "Duarte, California • Denver, Colorado • Fort Collins, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035253" }, { "nct_id": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-07-31", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06905509" }, { "nct_id": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer", "Minimal Residual Disease", "Colo-rectal Cancer", "Colon Cancer", "Rectal Cancer", "ctDNA Monitoring", "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Neoplasm, Residual", "Adenocarcinoma of Colon", "Adenocarcinoma" ], "interventions": [ { "name": "ALX148", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-02-15", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868226" }, { "nct_id": "NCT03959085", "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma", "Central Nervous System Leukemia", "Mixed Phenotype Acute Leukemia", "Testicular Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "25 Years", "sex": "ALL", "summary": "365 Days to 25 Years" }, "enrollment_count": 5951, "start_date": "2019-10-31", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-18T14:58:59.235Z", "location_count": 203, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959085" } ] }